What were the findings of the Study of Heart and Renal Protection? 
The Study of Heart and Renal Protection (SHARP) was a randomized placebo-controlled trial that investigated the effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease. The results of the study showed that the combination of simvastatin plus ezetimibe reduced the risk of major atherosclerotic events compared to placebo, with an overall risk reduction of 13%. Additionally, the combination of simvastatin plus ezetimibe was found to reduce the risk of all-cause mortality, cardiovascular mortality, and renal outcomes compared to placebo. 